ERLOTINIB TEVA 150 MG

Country: Israel

Language: English

Source: Ministry of Health

Active ingredient:

ERLOTINIB AS HYDROCHLORIDE

Available from:

TEVA ISRAEL LTD

ATC code:

L01XE03

Pharmaceutical form:

FILM COATED TABLETS

Composition:

ERLOTINIB AS HYDROCHLORIDE 150 MG

Administration route:

PER OS

Prescription type:

Required

Manufactured by:

TEVA ISRAEL LTD, ISRAEL

Therapeutic area:

ERLOTINIB

Therapeutic indications:

Non-Small Cell Lung Cancer (NSCLC): Erlotinib Teva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations. Erlotinib Teva is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations and stable disease after first-line chemotherapy. Erlotinib Teva is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.Pancreatic cancer: Erlotinib Teva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Authorization date:

2021-08-30

Patient Information leaflet

PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS’
REGULATIONS (PREPARATIONS) - 1986
The medicine is dispensed with a doctor’s prescription only
ERLOTINIB TEVA 100 MG
FILM-COATED TABLETS
ERLOTINIB TEVA 150 MG
FILM-COATED TABLETS
COMPOSITION
EACH FILM-COATED ERLOTINIB TEVA 100 MG TABLET CONTAINS:
Erlotinib 100 mg )as erlotinib hydrochloride(
EACH FILM-COATED ERLOTINIB TEVA 150 MG TABLET CONTAINS:
Erlotinib 150 mg )as erlotinib hydrochloride(
For information on inactive ingredients and allergens see section 2
under
‘Important information about some of this medicine’s
ingredients’ and
section 6 - ‘Additional information’.
READ THIS LEAFLET CAREFULLY IN ITS ENTIRETY BEFORE USING THE MEDICINE.
This leaflet contains concise information about the medicine. If you
have
further questions, refer to the doctor or pharmacist.
This medicine has been prescribed to treat your ailment. Do not pass
it
on to others. It may harm them even if it seems to you that their
ailment is
similar.
If you experience any side effects, refer to your doctor or
pharmacist. This
includes any possible side effects that are not listed in this leaflet
)see
section 4 - “Side Effects”(.
The medicine is not intended for use in children and adolescents below
the
age of 18.
IMPORTANT INFORMATION FOR YOUR REVIEW
•
Avoid pregnancy during the course of treatment with Erlotinib Teva,
and
do not breast-feed during the course of treatment with the medicine.
•
It is recommended that you stop smoking while under treatment with
Erlotinib Teva.
•
Take the medicine on an empty stomach - at least one hour before or
two
hours after completing a meal. Do not take the medicine with
grapefruits
or with grapefruit juice.
•
Erlotinib Teva contains a type of sugar called lactose.
1. WHAT IS THE MEDICINE INTENDED FOR?
THERAPEUTIC ACTIVITY:
Erlotinib Teva contains the active ingredient erlotinib. Erlotinib
Teva is a
medicine used to treat cancer by preventing the activity of a growth
factor
protein called EGFR )epidermal growth factor receptor(. Thi